Abstract
Objective To evaluate the clinical curative effect of zoledronic acid combined with 89Sr for the treatment of prostate cancer patients with bone metastases. Methods A total of 74 prostate cancer patients were randomly divided into three groups according to treatment, as follows: Group A (n= 25; median age, 66 years; age range, 46-87 years), zoledronic acid with 89Sr; Group B (n= 25; median age, 65 years; age range, 43-89 years), zoledronic acid; and Group C (n=24; median age, 66 years; age range, 47-85 years), 89Sr. Groups B and C were the control groups. All patients were followed up for 6 months, during which the status of bone pain relief and improvement in the number of bone metastatic lesions were observed. Results The three groups showed similar baseline characteristics. Total pain relief efficiency in group A was 88.0%, while those of the control groups were 72.0% (group B) and 79.2%(group C). Pain palliation of group A significantly differed from those of groups B and C (χ2=8.959, P<0.05). Regression of bone metastatic lesions in group A was 88.0%, while those of the control groups were 44.0% (group B) and 75.0% (group C). Significant difference was found between group A and the two control groups (χ2=9.096, P<0.05) . Conclusion Combined therapy of zoledronic acid and 89Sr in prostate cancer patients with painful bone metastases was more effective in treating pain and improving the quality of life than separate administration of zoledronic acid or 89Sr. Key words: Prostatic neoplasms; Strontium radioisotopes; Treatment outcome; Bone metastases; Zoledronic acid
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call